visitant ::
identificació
|
|||||||||||||||
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español |
Pàgina inicial > Articles > Articles publicats > Does Consumption of Ultra-Processed Foods Matter for Liver Health? Prospective Analysis among Older Adults with Metabolic Syndrome |
Data: | 2022 |
Resum: | Non-alcoholic fatty liver disease (NAFLD) includes a spectrum of liver alterations that can result in severe disease and even death. Consumption of ultra-processed foods (UPF) has been associated with obesity and related comorbidities. However, the link between UPF and NAFLD has not been sufficiently assessed. We aimed to investigate the prospective association between UPF consumption and liver health biomarkers. Methods: We followed for 1 year 5867 older participants with overweight/obesity and metabolic syndrome (MetS) from the PREDIMED-Plus trial. A validated 143-item semi-quantitative food frequency questionnaire was used to evaluate consumption of UPF at baseline, 6, and 12 months. The degree of processing for foods and beverages (g/day) was established according to the NOVA classification system. The non-invasive fatty liver index (FLI) and hepatic steatosis index (HSI) were used to evaluate liver health at three points in time. The associations between changes in UPF consumption (percentage of total daily dietary intake (g)) and liver biomarkers were assessed using mixed-effects linear models with repeated measurements. Results: In this cohort, UPF consumption at baseline was 8. 19% (SD 6. 95%) of total daily dietary intake in grams. In multivariable models, each 10% daily increment in UPF consumption in 1 year was associated with significantly greater FLI (β 1. 60 points, 95% CI 1. 24;1. 96 points) and HSI (0. 43, 0. 29; 0. 57) scores (all p -values < 0. 001). These associations persisted statistically significant after adjusting for potential dietary confounders and NAFLD risk factors. Conclusions: A higher UPF consumption was associated with higher levels of NAFLD-related biomarkers in older adults with overweight/obesity and MetS. |
Ajuts: | European Research Council 340918 Instituto de Salud Carlos III PI13/00673 Instituto de Salud Carlos III PI13/00492 Instituto de Salud Carlos III PI13/00272 Instituto de Salud Carlos III PI13/01123 Instituto de Salud Carlos III PI13/00462 Instituto de Salud Carlos III PI13/00233 Instituto de Salud Carlos III PI13/02184 Instituto de Salud Carlos III PI13/00728 Instituto de Salud Carlos III PI13/01090 Instituto de Salud Carlos III PI13/01056 Instituto de Salud Carlos III PI14/01722 Instituto de Salud Carlos III PI14/00636 Instituto de Salud Carlos III PI14/00618 Instituto de Salud Carlos III PI14/00696 Instituto de Salud Carlos III PI14/01206 Instituto de Salud Carlos III PI14/01919 Instituto de Salud Carlos III PI14/00853 Instituto de Salud Carlos III PI14/01374 Instituto de Salud Carlos III PI14/00972 Instituto de Salud Carlos III PI14/00728 Instituto de Salud Carlos III PI14/01471 Instituto de Salud Carlos III PI16/00473 Instituto de Salud Carlos III PI16/00662 Instituto de Salud Carlos III PI16/01873 Instituto de Salud Carlos III PI16/01094 Instituto de Salud Carlos III PI16/00501 Instituto de Salud Carlos III PI16/00533 Instituto de Salud Carlos III PI16/00381 Instituto de Salud Carlos III PI16/00366 Instituto de Salud Carlos III PI16/01522 Instituto de Salud Carlos III PI16/01120 Instituto de Salud Carlos III PI17/00764 Instituto de Salud Carlos III PI17/01183 Instituto de Salud Carlos III PI17/00855 Instituto de Salud Carlos III PI17/01347 Instituto de Salud Carlos III PI17/00525 Instituto de Salud Carlos III PI17/01827 Instituto de Salud Carlos III PI17/00532 Instituto de Salud Carlos III PI17/00215 Instituto de Salud Carlos III PI17/01441 Instituto de Salud Carlos III PI17/00508 Instituto de Salud Carlos III PI17/01732 Instituto de Salud Carlos III PI17/00926 Instituto de Salud Carlos III PI19/00957 Instituto de Salud Carlos III PI19/00386 Instituto de Salud Carlos III PI19/00309 Instituto de Salud Carlos III PI19/01032 Instituto de Salud Carlos III PI19/00576 Instituto de Salud Carlos III PI19/00017 Instituto de Salud Carlos III PI19/01226 Instituto de Salud Carlos III PI19/00781 Instituto de Salud Carlos III PI19/01560 Instituto de Salud Carlos III PI19/01332 Instituto de Salud Carlos III PI20/01802 Instituto de Salud Carlos III PI20/00138 Instituto de Salud Carlos III PI20/01532 Instituto de Salud Carlos III PI20/00456 Instituto de Salud Carlos III PI20/00339 Instituto de Salud Carlos III PI20/00557 Instituto de Salud Carlos III PI20/00886 Instituto de Salud Carlos III PI20/01158 Instituto de Salud Carlos III PI21/00465 Instituto de Salud Carlos III CPII20/00014 "la Caixa" Foundation 2013ACUP00194 Ministerio de Economía y Competitividad IJC2019-042420-I |
Nota: | Altres ajuts: Generalitat Valenciana PROMETEO/2017/017 |
Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
Llengua: | Anglès |
Document: | Article ; recerca ; Versió publicada |
Matèria: | Ultra-processed foods ; Liver health markers ; Fatty liver index ; Hepatic steatosis index ; Metabolic syndrome |
Publicat a: | Nutrients, Vol. 14 (october 2022) , ISSN 2072-6643 |
21 p, 1.1 MB |